Treatment, Outcomes, Costs, and Quality of Life of Women and Men With Acute Coronary Syndromes Who Have Undergone Percutaneous Coronary Intervention: Results From the Antiplatelet Therapy Observational Registry
Key result
Women with acute coronary syndromes undergoing PCI had similar 12-month clinical outcomes to men, but reported lower quality of life and higher mean total costs (£6252 vs £5841).
Why the study?
Does female sex affect treatment, outcomes, costs, and quality of life in patients with acute coronary syndromes undergoing percutaneous coronary intervention compared to male sex?
Population
4546 patients with acute coronary syndromes who underwent percutaneous coronary intervention from 2007 to…
Comparison
Female sex (observational comparison) vs Male sex
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Sex should not alter PCI decisions in ACS; leaves open mechanisms of QoL and cost differences in women.
Study Design
Type
Cohort (n=4,546)
Multicenter
Yes
Structured PICO
Does female sex affect treatment, outcomes, costs, and quality of life in patients with acute coronary syndromes undergoing percutaneous coronary intervention compared to male sex?
P
Population
4546 patients with acute coronary syndromes (ACS) who underwent percutaneous coronary intervention (PCI) from 2007 to 2009 across 14 European countries (1047 women, 3499 men). Women mean age 67, men mean age 61.
I
Intervention
Female sex (observational comparison)
C
Comparator
Male sex
O
Outcome
12-month outcomes including bleeding, cardiovascular events, and mortalityhard clinical
Women with ACS undergoing PCI have more comorbidities and lower quality of life at 1 year compared to men, but experience similar clinical outcomes and receive similar treatments.
Cite This Study
Bakhai et al. (2013) conducted a cohort in Acute Coronary Syndromes (n=4,546). Female sex vs. Male sex was evaluated on Bleeding, cardiovascular events, and mortality. Women with acute coronary syndromes undergoing PCI had similar 12-month clinical outcomes to men, but reported lower quality of life and higher mean total costs (£6252 vs £5841).